TM Owner Roche
Tecentriq Hybreza 1875mg/15ml Vial
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) 1,875 mg/15 mL is a subcutaneous formulation of the checkpoint inhibitor atezolizumab, combined with an enzyme (hyaluronidase) that allows the antibody to be injected under the skin instead of into a vein.
- Approved in the US in 2024, it carries the same range of adult indications as intravenous Tecentriq: non-small cell lung cancer (adjuvant and first-line metastatic, alone or combined with chemotherapy), extensive-stage small-cell lung cancer, unresectable or metastatic hepatocellular carcinoma with bevacizumab, BRAF V600 mutation-positive melanoma, alveolar soft part sarcoma in patients 12 years and older weighing at least 40 kg, and adjuvant treatment of muscle-invasive bladder cancer.
- Tecentriq Hybreza is a genuinely different formulation from intravenous Tecentriq, dosed and injected differently, and the two are not interchangeable milliliter-for-milliliter.
- Outside the US, subcutaneous atezolizumab may be marketed under the Tecentriq name itself rather than as 'Hybreza.'
Side Effects
- Because Tecentriq Hybreza contains the same active antibody as intravenous Tecentriq, its side-effect profile is similar: very common effects include tiredness, decreased appetite, nausea, cough, shortness of breath, rash, fever, joint pain and low blood counts when combined with chemotherapy.
- There is no boxed warning, but serious immune-mediated reactions can affect the lungs, bowel, liver, hormone glands, skin, kidneys, nerves and heart, and can appear weeks after the last dose; report new cough, breathlessness, severe diarrhea, yellowing skin, unusual fatigue, muscle weakness or chest pain promptly.
- The subcutaneous injection itself commonly causes local site reactions such as pain, redness, itching or swelling in the thigh, and general injection-related reactions such as chills, fever or nausea can occur, usually within the first hour of dosing.
Precautions & Warnings
- Tecentriq Hybreza is given only by a healthcare professional as a subcutaneous injection into the thigh over about 7 minutes every three weeks, alternating sides and avoiding skin that is red, bruised, tender or scarred; it must not be given intravenously.
- As with intravenous atezolizumab, baseline and periodic monitoring of liver enzymes, kidney function, thyroid hormones and blood glucose is required, and treatment is paused with corticosteroid treatment started if immune-mediated inflammation develops in any organ.
- It should be avoided in active autoimmune disease needing systemic treatment unless your specialist judges the benefit outweighs the risk.
- Effective contraception is required during treatment and for 5 months after the last dose because of possible fetal harm; it is not used in pregnancy or breastfeeding.
- Tell your care team about any bleeding disorder or anticoagulant use, since subcutaneous injections carry a small bruising risk.
Avoid Interactions
- As a large protein antibody-enzyme combination, Tecentriq Hybreza has few classical pharmacokinetic drug interactions, but tell your healthcare provider about every medicine and supplement you use.
- Anticoagulants and antiplatelet medicines can increase bruising or bleeding at the subcutaneous injection site because hyaluronidase temporarily increases local tissue permeability.
- Systemic corticosteroids or other immunosuppressants started before treatment may lessen how well atezolizumab works, though they remain appropriate once used to treat an immune-related side effect.
- Live vaccines should generally be avoided during treatment.
- When combined with chemotherapy, bevacizumab or other targeted cancer drugs, each partner medicine has its own separate interaction profile that must be reviewed by your oncology team.
- Do not mix Tecentriq Hybreza with other medicines in the same syringe.
References
Frequently Asked Questions
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) is a subcutaneous immunotherapy used in adults with certain lung, liver and skin cancers, a rare sarcoma, and bladder cancer, covering most of the same uses as intravenous Tecentriq. It helps your immune system attack cancer cells by blocking the PD-L1 protein.
Tecentriq Hybreza is injected under the skin of the thigh over about 7 minutes, usually every 3 weeks, by a healthcare professional in a clinic or hospital. It is not given into a vein and cannot be self-injected at home. Injection sites are alternated each time.
Common side effects of Tecentriq Hybreza (atezolizumab) include tiredness, nausea, low appetite, cough, joint pain and injection-site reactions like redness or swelling. It can also cause serious immune-mediated inflammation of the lungs, bowel, liver or thyroid. Report new breathlessness, severe diarrhea, yellowing skin or unusual fatigue urgently.
Avoid live vaccines during Tecentriq Hybreza treatment, since it stimulates your immune system. Blood-thinning medicines can increase bruising at the injection site. Effective contraception is required during treatment and for 5 months after the last dose, as atezolizumab may harm an unborn baby; it is not used in pregnancy.
No. Tecentriq Hybreza is a distinct subcutaneous formulation combining atezolizumab with hyaluronidase, dosed and injected differently from intravenous Tecentriq. The two are not interchangeable milliliter-for-milliliter. Your oncology team chooses which formulation and schedule fits your treatment plan.
Tecentriq Hybreza is injected into the thigh, alternating sides each dose, avoiding skin that is red, bruised, tender or scarred. It is given by a trained healthcare professional, never into a vein. The injection itself takes about 7 minutes, followed by a period of monitoring for reactions.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
